Cross-sectional Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Between 18 and 64 Years Old Using the Vaccinees Perception of Injection
CompletedOBSERVATIONAL
Enrollment
447
Participants
Timeline
Start Date
November 18, 2024
Primary Completion Date
January 4, 2025
Study Completion Date
January 4, 2025
Conditions
Influenza ImmunizationHealth Volunteers
Interventions
BIOLOGICAL
RIV3
intramuscular injection
Trial Locations (1)
18370
Investigational site, Swiftwater
All Listed Sponsors
lead
Sanofi Pasteur, a Sanofi Company
INDUSTRY
NCT06765187 - Cross-sectional Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Between 18 and 64 Years Old Using the Vaccinees Perception of Injection | Biotech Hunter | Biotech Hunter